Letter to the Editor - Devices regulation in the UK
This article was originally published in Clinica
Two weeks ago, we printed a feature in which some of the UK devices sector's key players decried the lower regulatory profile of their industry in the year and a half since devices and pharma regulation were merged under the all-embracing Medicines and Healthcare products Regulatory Agency (MHRA). On pages 4-8 of Clinica No 1133, interested and concerned parties - MP Ian Gibson, BIVDA (for the diagnostics industry), and the BHTA among them - bemoaned the decision not to install a dedicated head of UK devices regulation. Some observers considered that credible reasons for this were not given at the inception of the MHRA, and are no less reassured 18 months later. We approached MHRA chief executive Professor Kent Woods for his comments on the debate that has emerged, but internal MHRA procedures prevented him from talking to us. Here, he gives a written response.
You may also be interested in...
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.